Volume 60, Issue 1 pp. 143-145
Brief Report

Extraneural ependymoma: Distant bone, lung, liver, and lymph node metastases following bevacizumab

Cheryl Fischer CPNP

Cheryl Fischer CPNP

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York City, New York

Search for more papers by this author
Sofia S. Haque MD

Sofia S. Haque MD

Department of Radiology, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center, New York City, New York

Search for more papers by this author
Jason T. Huse MD, PhD

Jason T. Huse MD, PhD

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York City, New York

Search for more papers by this author
Elen Blochin MD

Elen Blochin MD

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York City, New York

Search for more papers by this author
Mark M. Souweidane MD

Mark M. Souweidane MD

Department of Neurologic Surgery, Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York City, New York

Search for more papers by this author
Eric Lis MD

Eric Lis MD

Department of Radiology, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center, New York City, New York

Search for more papers by this author
Yasmin Khakoo MD

Corresponding Author

Yasmin Khakoo MD

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York City, New York

Department of Pediatrics, Weill Cornell Medical College, New York City, New York

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 410 E 68th Street, Box 565, New York, NY 10065.===Search for more papers by this author
First published: 13 September 2012
Citations: 13

Conflict of interest: Nothing to report.

Abstract

Extraneural metastases of ependymoma are rare, and have been reported in the lungs, lymph nodes, pleura, mediastinum, liver, diaphragmatic muscle, and bone. We report a case of anaplastic ependymoma with distant metastases to the vertebral bones, lungs, liver, and lymph nodes following treatment with bevacizumab. Recent research has hypothesized that angiogenic tumors may develop means of resistance to antiangiogenic therapies, and some evidence suggests potential for antiangiogenic therapies to promote additional means for cancer spread. Nevertheless, antiangiogenic therapies continue to demonstrate potential as potent therapies for the treatment of many cancers, and should continue to be researched for future uses. Pediatr Blood Cancer 2013; 60: 143–145. © 2012 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.